Skip to main content
OpenTrials

Clinical trial condition

PDAC

Explore clinical trials studying PDAC. Study availability and eligibility vary by location and protocol.

22 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

PDAC trial results

Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT06597721

Conditions
Advanced Solid Tumor, Carcinoma, Carcinoma, Squamous Cell, +8 more
Locations
  • Highlands Oncology Group Rogers, Arkansas, United States
  • Yale University Cancer Center New Haven, Connecticut, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View all 14 locations
View Trial Details
Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +17 more
Locations
  • City of Hope Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Medical Oncology Hematology Consultants Newark, Delaware, United States
  • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
View all 43 locations
View Trial Details
Recruiting

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT07490301

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Locations
  • City Of Hope - Chicago /ID# 279814 Zion, Illinois, United States
  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853 Grand Rapids, Michigan, United States
  • Texas Oncology - Northeast Texas /ID# 280417 Tyler, Texas, United States
  • Virginia Cancer Specialists - Fairfax /ID# 280415 Fairfax, Virginia, United States
View all 19 locations
View Trial Details
Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +13 more
Locations
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 33 locations
View Trial Details
Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
Locations
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • University of California, San Francisco San Francisco, California, United States
View all 66 locations
View Trial Details
Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +13 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Piedmont Healthcare Atlanta, Georgia, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Johns Hopkins University Baltimore, Maryland, United States
View Trial Details
Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT07349537

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, CRC, +30 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • Johns Hopkins Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • START Midwest Grand Rapids, Michigan, United States
View Trial Details
Recruiting

Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

NCT07145450

Conditions
PDAC
Locations
  • Herlev and Gentofte University Hospital Copenhagen, Denmark
  • Charité Universitätsmedizin Berlin Berlin, Germany
  • Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus Dresden, Germany
  • Universitaetsklinikum Heidelberg Heidelberg, Germany
View Trial Details

Related conditions